Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of High-Risk Patients with SARS-CoV-2 Delta Variant Infection
Noah Shopen, Michal Dekel, Michal Mizrahi, Efrat Zandberg, Nancy Bishouty, Daniel Talmud, Ben Vaknin, Shira Haberman, Malka Katz Shalhav, David Zeltser, MD Neta Cohen
doi:10.1101/2022.01.29.22270090
Casirivimab/Imdevimab therapy reportedly retains neutralization potency against circulating SARS-CoV-2 variants, including Delta (B.1.617.2), but there are sparse data on its clinical benefit against the Delta variant among vaccinated and unvaccinated patients. We explored its therapeutic effect on COVID-19 severity outcome in terms of room air saturation <93% within 14 days of initial presentation and 45-day all-cause mortality among high-risk patients with SARS-CoV-2 Delta variant infection and compared its effect between vaccinated and unvaccinated patients. We conducted a retrospective cohort study at a tertiary care medical center between 6/2021 and 9/2021 and included patients who presented with a positive PCR for SARS-CoV-2 and fulfilled the criteria for Casirivimab/Imdevimab treatment. Of the 359 suitable patients (52% female, median age 63 years), 116 were treated with Casirivimab/Imdevimab and 243 were not. Two-hundred and one (56%) patients had received at least 2 SARS-CoV-2 vaccinations. Casirivimab/Imdevimab treatment was not an independent protective factor of COVID-19 severity outcome (multivariable analysis). Chronic kidney disease (aOR=3.51 [95%CI: 1.34-9.20], P=0.01), lower saturation levels (aOR=0.7 [95%CI: 0.58-0.85], P<0.01), abnormal chest x-ray findings (aOR=2.92, [95%CI: 1.24-6.87, P=0.01), and higher C-reactive protein levels (aOR=1.01 [95%CI: 1.00-1.01], P=0.008) were independent risk factors of COVID-19 severity. Positive immunization status was an independent protective factor (aOR=0.33 [95%CI: 0.14-0.77], P=0.01). A sub analysis of patients treated with Casirivimab/Imdevimab revealed no significant difference in COVID-19 severity between vaccinated and unvaccinated patients. These findings demonstrate no added benefit of Casrivimab/Imdevinab treatment for high-risk patients with the SARS-CoV-2 Delta variant infection, regardless of their vaccination status.
References
Balbi, Caroli, Corsi, Milanese, Surace et al., Chest X-ray for predicting mortality and the need for ventilatory support in COVID-19 patients presenting to the emergency department, Eur Radiol,
doi:10.1007/s00330-020-07270-1Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science
Bierle, Ganesh, Tulledge-Scheitel, Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities
Bierle, Ganesh, Wilker, Hanson, Moehnke et al., Influence of Social and Cultural Factors on the Decision to Consent for Monoclonal Antibody Treatment among High-Risk Patients with Mild-Moderate COVID-19, J Prim Care Community Health,
doi:10.1177/21501327211019282Cameroni, Saliba, Bowen, Rosen, Culap et al., Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift bioRxiv,
doi:10.1101/2021.12.12.472269Casirivimab + Imdevimab Injection, Elliott, William, Chan, None, Internal Medicine Alert and Atlanta
Copin, Baum, Wloga, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, Cell
Cozzi, Albanesi, Cavigli, Moroni, Bindi et al., Chest X-ray in new Coronavirus Disease 2019 (COVID-19) infection: findings and correlation with clinical outcome, Radiol Med,
doi:10.1007/s11547-020-01232-9Docherty, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterization Protocol: prospective observational cohort study, BMJ
Embi, Levy, Naleway, Patel, Gaglani et al., Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults -Nine States, January, MMWR Morbidity and mortality weekly report
Falcone, Tiseo, Valoriani, Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern, Infect Dis Ther,
doi:10.1007/s40121-021-00525-4Fda, Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19
Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019, J Infect Dis,
doi:10.1093/infdis/jiab377Gao, Dong, Risk Factors for Severe and Critically Ill COVID 19 Patients: A Review, Allergy (Copenhagen)
Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA,
doi:10.1001/jama.2021.0202Haas, Angulo, Mclaughlin, Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data, Lancet
He, He, Hong, Zhang, Wei, The challenges of COVID-19 Delta variant: Prevention and vaccine development
Horby, Mafham, Peto, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Mair, Berger, Berghoff, Starzer, Ortmayr et al., Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations, JAMA Oncology
Marrams, Kobayashi, Suzuki, patients: a systematic literature review and meta-analysis
Planas, Saunders, Maes, Guivel-Benhassine, Planchais et al., Considerable escape of SARS-CoV-2 variant Omicron to antibody neutralization, bioRxiv,
doi:10.1101/2021.12.14.472630Tabata, Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis, Lancet Infect. Dis
Von Elm, Altman, Egger, Pocock, Gøtzsche et al., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies, Lancet
Wang, Nair, Liu, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Williamson, Walker, Bhaskaran, Factors associ-ated with COVID-19-related death using OpenSAFELY, Nature
Zhang, Cao, Tan, Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients, Allergy
{ 'institution': [{'name': 'medRxiv'}],
'indexed': {'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T21:41:28Z', 'timestamp': 1643665288563},
'posted': {'date-parts': [[2022, 1, 31]]},
'group-title': 'Emergency Medicine',
'reference-count': 0,
'publisher': 'Cold Spring Harbor Laboratory',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'short-container-title': [],
'accepted': {'date-parts': [[2022, 1, 31]]},
'abstract': '<jats:p>Casirivimab/Imdevimab therapy reportedly retains neutralization potency against '
'circulating SARS-CoV-2 variants, including Delta (B.1.617.2), but there are sparse data on '
'its clinical benefit against the Delta variant among vaccinated and unvaccinated patients. We '
'explored its therapeutic effect on COVID-19 severity outcome in terms of room air saturation '
'<93% within 14 days of initial presentation and 45 day all cause mortality among high-risk '
'patients with SARS-CoV-2 Delta variant infection and compared its effect between vaccinated '
'and unvaccinated patients. We conducted a retrospective cohort study at a tertiary care '
'medical center between 6/2021 and 9/2021 and included patients who presented with a positive '
'PCR for SARS-CoV-2 and fulfilled the criteria for Casirivimab/Imdevimab treatment. Of the 359 '
'suitable patients (52% female, median age 63 years), 116 were treated with '
'Casirivimab/Imdevimab and 243 were not. Two hundred and one (56%) patients had received at '
'least 2 SARS-CoV-2 vaccinations. Casirivimab/Imdevimab treatment was not an independent '
'protective factor of COVID 19 severity outcome (multivariable analysis). Chronic kidney '
'disease (aOR=3.51 [95%CI: 1.34 to 9.20], P=0.01), lower saturation levels (aOR=0.7 [95%CI: '
'0.58 to 0.85], P<0.01), abnormal chest x ray findings (aOR=2.92, [95%CI: 1.24 to 6.87, '
'P=0.01), and higher C-reactive protein levels (aOR=1.01 [95%CI: 1.00 to 1.01], P=0.008) were '
'independent risk factors of COVID-19 severity. Positive immunization status was an '
'independent protective factor (aOR=0.33 [95%CI: 0.14 to 0.77], P=0.01). A sub analysis of '
'patients treated with Casirivimab/Imdevimab revealed no significant difference in COVID-19 '
'severity between vaccinated and unvaccinated patients. These findings demonstrate no added '
'benefit of Casrivimab/Imdevinab treatment for high-risk patients with the SARS-CoV-2 Delta '
'variant infection, regardless of their vaccination status.</jats:p>',
'DOI': '10.1101/2022.01.29.22270090',
'type': 'posted-content',
'created': {'date-parts': [[2022, 1, 31]], 'date-time': '2022-01-31T21:10:26Z', 'timestamp': 1643663426000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': [ 'Doubtful Clinical Benefit of Casirivimab-Imdevimab Treatment for Disease Severity Outcome of '
'High-Risk Patients with SARS-CoV-2 Delta Variant Infection'],
'prefix': '10.1101',
'author': [ {'given': 'Noah', 'family': 'Shopen', 'sequence': 'first', 'affiliation': []},
{'given': 'Michal', 'family': 'Dekel', 'sequence': 'additional', 'affiliation': []},
{'given': 'Michal', 'family': 'Mizrahi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Efrat', 'family': 'Zandberg', 'sequence': 'additional', 'affiliation': []},
{'given': 'Nancy', 'family': 'Bishouty', 'sequence': 'additional', 'affiliation': []},
{'given': 'Daniel', 'family': 'Talmud', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ben', 'family': 'Vaknin', 'sequence': 'additional', 'affiliation': []},
{'given': 'Shira', 'family': 'Haberman', 'sequence': 'additional', 'affiliation': []},
{'given': 'Malka', 'family': 'Katz Shalhav', 'sequence': 'additional', 'affiliation': []},
{'given': 'David', 'family': 'Zeltser', 'sequence': 'additional', 'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0001-7694-6407',
'authenticated-orcid': False,
'given': 'Neta',
'family': 'Cohen',
'sequence': 'additional',
'affiliation': []}],
'member': '246',
'container-title': [],
'original-title': [],
'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.01.29.22270090',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2022, 1, 31]],
'date-time': '2022-01-31T21:10:26Z',
'timestamp': 1643663426000},
'score': 1,
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2022, 1, 31]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.1101/2022.01.29.22270090',
'relation': {},
'published': {'date-parts': [[2022, 1, 31]]},
'subtype': 'preprint'}
